Navigation Links
Protein protects against breast cancer recurrence in animal model

PHILADELPHIA - According to the American Cancer Society, nearly 40,000 women in the United States will succumb to breast cancer this year. Most of these women will die not from the primary tumor but rather tumor recurrence the reappearance of the disease following treatment.

Precisely what causes breast cancer recurrence has been poorly understood. But now a piece of the puzzle has fallen into place: Researchers at the Perelman School of Medicine, University of Pennsylvania have identified a key molecular player in recurrent breast cancer a finding that suggests potential new therapeutic strategies.

The study, performed in the laboratory of Lewis A. Chodosh MD, PhD, chair of Cancer Biology and director of Cancer Genetics at the Abramson Family Cancer Research Institute, implicates the tumor suppressor protein Par-4 in recurrent breast cancer.

Par-4 is downregulated in recurrent tumors, and knocking the gene's expression down accelerates tumor recurrence in a mouse model of recurrent breast cancer. Conversely, overexpressing Par-4 delays the onset of tumor recurrence.

Data from human breast cancer patients confirm these findings. The authors analyzed patient tumors from the I-SPY 1 TRIAL, a clinical trial that measured tumor gene expression patterns and response to neoadjuvant chemotherapy. They found that Par-4 expression is low in "residual disease" (that portion of a tumor that survives chemotherapy) compared to the primary tumor prior to treatment, and that women with low Par-4 levels in their primary tumors tend to respond less well to treatment and are more likely to experience a relapse.

The findings appear in this week's issue of Cancer Cell.

The study was led by Chodosh senior postdoctoral fellow, James V. Alvarez, PhD. Alvarez and his colleagues teased apart the role of Par-4 using a mouse model of recurrent breast cancer. In this model, turning "on" the HER2/neu oncogene in mice -- which is turned on in about 20% of human breast cancers -- induces the formation of a primary mammary tumor. Subsequently, turning HER2/neu "off" in a tumor that has arisen causes it to essentially disappear, mimicking the treatment of primary human breast cancers with the anti-HER2/neu agent, Herceptin. But, as in many human patients, at some point in the weeks and months following tumor regression, tumors often return, both in the breast as well as in secondary sites such as the lungs.

By studying these paired primary and recurrent tumors, Alvarez, Chodosh, and their colleagues found that Par-4 expression was dialed down in recurrent tumors relative to primary tumors. When they examined gene expression data from human breast cancer specimens, they found that low Par-4 expression was associated with an increased risk of recurrence and a poorer response to neoadjuvant therapy -- chemotherapy prior to surgery. A poor response to neoadjuvant therapy is associated with an increased likelihood of recurrence.

Based on these findings, the team hypothesized that cells that downregulate Par-4 may be more adept at surviving chemotherapeutic treatment of the primary tumor, and that's precisely what they found. When they compared cells expressing normal levels of Par-4 with cells that had downregulated the gene, they found that it is the cells with low Par-4 levels that persist following treatment. Consequently, it is these cells that are available to give rise to recurrent tumors in the future.

The team then asked what Par-4 actually does to prevent breast cancer recurrence. They found in their mouse models that when HER2/neu is turned off and primary tumors shrink, Par-4 expression ramps up. This causes a defect in cell division, producing cells with more than one nucleus. This, in turn, leads to cell death. Cells that have downregulated Par-4 fail are able to escape this multinucleation process, allowing them to survive therapy and, eventually, give rise to a recurrent tumor.

The bottom line, Alvarez says, is that Par-4 downregulation is both a necessary and sufficient step for breast tumor recurrence. "Par-4 downregulation allows tumor cells to survive tumor regression caused by oncogene inhibition or chemotherapy."

That conclusion suggests that strategies that increase Par-4 expression in tumors could pay therapeutic dividends. In fact, turning Par-4 back on in recurrent tumor cells led to their rapid death. However, "drugging' Par-4 won't be easy", he says.

Par-4 is a tumor suppressor protein that functions through interactions with other proteins. Neither an enzyme nor a signaling receptor, it is not a traditionally "druggable" molecule. However, if researchers can identify the biochemical pathway that controls Par-4, or molecules that can modulate Par-4 activity directly, they may be able to increase the efficacy of neoadjuvant therapy of primary tumors as well as treat recurrent breast cancers more effectively, Alvarez says. The team is now working on identifying pathways that regulate Par-4 levels.


Contact: Karen Kreeger
University of Pennsylvania School of Medicine

Related medicine news :

1. Warwick scientists uncover how checkpoint proteins bind chromosomes
2. Specific protein triggers changes in neurons in brain reward center linked to cocaine addiction
3. Unusual protein helps regulate key cell communication pathway
4. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
5. RANK protein promotes the initiation, progression and metastasis of human breast cancer
6. Protein may represent a switch to turn off B cell lymphoma
7. Protein RAL associated with aggressive characteristics in prostate, bladder and skin cancers
8. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
9. Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease
10. New molecular structure offers first picture of a protein family vital to human health
11. Wayne State University researcher examines proteins role in diabetic retinopathy
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: